FDA to review 5-in-1 meningococcal vaccine candidate
The vaccine candidate covers the five groups of Neisseria meningitidis bacteria that cause most cases of invasive meningococcal disease.
The vaccine candidate covers the five groups of Neisseria meningitidis bacteria that cause most cases of invasive meningococcal disease.
Four years after a mysterious respiratory virus jumped from animals into humans and launched the COVID pandemic, wary epidemiologists are keeping a close eye on…
At the end of May, 194 member states of the World Health Organization (WHO) will meet for the World Health Assembly. Negotiations underway now will…
Part of a national rise, Colorado has confirmed 25 cases this year, which included 5 stillbirths and 2 neonatal deaths.
In pediatric myeloablative allogeneic hematopoietic cell transplantation recipients, pre-transplant symptomatic upper respiratory tract infections, includi
In the vaccine group there were 9 seizure events reported.
Opinion: Examine a summary of studies on how COVID-19 may damage the brain’s frontal lobes, alter personality traits and cognitive functions, and potentially reshape society’s…
Lisa Pawlowski, DNP, MSN-Ed, RN, CRMST, presents a poster at the HSPA 2024 Conference highlighting an evidence-based bundle that reduces SSIs by improving post-use instrument…
The U.S. Department of Agriculture said on Monday it is collecting samples of ground beef at retail stores in states with outbreaks of bird flu…
Noah Wald-Dickler, MD, FACP, discusses the safety and efficacy of oral transition therapy, challenges in antimicrobial stewardship, and evidence-based alternatives presented at SHEA 2024.
Researchers evaluated the effectiveness of the 2023-2024 formulation of the mRNA COVID-19 vaccine among employees at a health system in Cleveland, Ohio.